Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting 3
NCT02406781 Phase II Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) Active, not recruiting 1
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting USA 0
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Recruiting USA | CAN 2
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Recruiting 3
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Recruiting USA 1
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Recruiting USA 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04906876 Phase II 9-ING-41 + Docetaxel + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT05017103 Phase II Sintilimab Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study Recruiting USA 0
NCT05116800 Phase II 9-ING-41 + Docetaxel + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05182164 Phase II Cabozantinib + Pembrolizumab Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) Not yet recruiting 1